Épidémiologie du cancer de l’ovaire

  • C. Lasset
Part of the Abord clinique book series (ONCOLPRAT)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Remontet L et al. (2003) Évolution de l’incidence et de la mortalité par cancer en France de 1978 à 2000. Saint-Maurice: Institut de veille sanitaireGoogle Scholar
  2. 2.
    Hill C, Doyon F (2005) La fréquence des cancers en France en 2000 et son évolution depuis 1950. Bull cancer 92: 7–11PubMedGoogle Scholar
  3. 3.
    Nguyen H et al. (1994) Ovarian carcinoma. A review of the significance of familial risk factors and the role of prophylactic oophorectomy in cancer prevention. Cancer 74: 545–55PubMedGoogle Scholar
  4. 4.
    Riman T et al. (2002) Risks factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 156: 363–373CrossRefPubMedGoogle Scholar
  5. 5.
    Banks E et al. (1997) The epidemiology of epithelial ovarian cancer: a review. Int J Gynecol Cancer 7: 425–38CrossRefGoogle Scholar
  6. 6.
    Whittemore A et al. (1992) The Collaborative Ovarian Group. Characteristics relating ovarian cancer risk: collaborative analysis of 12 case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 136: 1184–202PubMedGoogle Scholar
  7. 7.
    Whiteman D et al. (2003) Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 12: 42–46PubMedGoogle Scholar
  8. 8.
    La Vecchia C et al. (2001) Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst 93: 319–20PubMedGoogle Scholar
  9. 9.
    IARC (1999) Working Group on the Evaluation of Carcinogenic Risks in Humans. Hormonal contraception and postmenopausal hormonal therapy. IARC Monograph 72. Lyon (France): IARC PressGoogle Scholar
  10. 10.
    Franceschi S et al. (1991) Pooled analysis of 3 european case-control studies of epithelial ovarian cancer III Oral contraceptive use. Int J Cancer 49: 61–5PubMedGoogle Scholar
  11. 11.
    Ness R et al. (2000) Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE study group. Steroids Hormones and Reproductions. Am J Epidemiol 152: 233–41CrossRefPubMedGoogle Scholar
  12. 12.
    Riman T et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002; 94: 497–504PubMedGoogle Scholar
  13. 13.
    Anderson G et al. (2003) Effects of estrogen plus progestin on gynaecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 1739–48Google Scholar
  14. 14.
    Schildkraut J et al. (1996) Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 88: 554–9CrossRefPubMedGoogle Scholar
  15. 15.
    Ness R et al. (2003) Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 189: 280–94CrossRefPubMedGoogle Scholar
  16. 16.
    Ness R et al. (2002) Infertility, fertility drugs and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 155: 217–24CrossRefPubMedGoogle Scholar
  17. 17.
    Le G et al. (2002) Cancer incidence patterns among Vietnamese in the United Stats and Ha Noi, Vietnam. Int J Cancer 102: 412–7CrossRefPubMedGoogle Scholar
  18. 18.
    Calle E et al. (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348: 1625–38CrossRefPubMedGoogle Scholar
  19. 19.
    Lubin F et al. (2002) Body mass index in relation to ovarian cancer: a multi-centre nested case-control study. Int J Cancer 99: 603–8Google Scholar
  20. 20.
    Lukanova A et al. (2005) Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 14: 98–107PubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • C. Lasset

There are no affiliations available

Personalised recommendations